Coherently with this function, HEIH was found to promote malignant phenotypes by competitively binding miR-4458 to upregulate the expression of SOCS1and PBX3 in breast cancer and esophageal cancer, respectively [33, 51]. Here, HEIH is linked to breast carcinoma.